The Catalan company Rob Surgical, specialising in robotic technology for minimally invasive surgery and a member of Catalonia.health, has inaugurated its first manufacturing plant in El Prat de Llobregat (Barcelona). This facility marks a turning point for the company in its industrialisation phase and paves the way for the commercial launch of its surgical system Bitrack, designed for high-precision soft-tissue procedures.
The new 500 m² plant has an initial production capacity of 15 to 20 robots per year and forms part of an investment plan of €50 million over the coming years. This investment will support both the commercial launch of the Bitrack system and the expansion of its industrialisation, as well as the development of a broader portfolio of surgical instruments.
The Bitrack system is currently in the final stages of obtaining CE marking, a prerequisite for its commercialisation in Spain and across the European Union. The robot is intended for minimally invasive surgery in specialties such as urology, gynaecology and gastroenterology, with the aim of making precision-technology procedures more accessible and efficient.
The inauguration event was attended by several institutional authorities, including the Minister of Industry, Jordi Hereu, as well as representatives from the sector and members of the Rob Surgical management team.
This new growth phase is also accompanied by significant changes in the company’s shareholder structure and management. Scranton Enterprises, Rob Surgical’s leading shareholder, capitalised loans worth €19.1 million last summer, increasing its stake from 47% to 67%. At the same time, the company appointed Mario Ferradosa as its new Chief Executive Officer, an executive with more than 30 years of experience at Johnson & Johnson. Meanwhile, Jaume Amat, founding partner and former CEO, remains involved in the project as a member of the Board of Directors.
“The launch of this plant represents a fundamental step in integrating the industrial process of Bitrack ahead of its market launch,” said Mario Ferradosa, CEO of Rob Surgical. “Having our own manufacturing facility exemplifies the company’s ambition to build a long-term industrial project with high added value, strong local roots and partners, and an international outlook,” added Jaume Amat, founding partner of Rob Surgical.
Comments